The Prevalence of Hepatitis C Virus (HCV) Infection and Genotypes in Patients with Hemophilia and Other Blood Coagulopathies in Mashhad, Iran

Background and Aim: Patients with blood coagulopathies treated with multiple transfusions have a high risk to acquire some viral infections such as hepatitis C. This research was aimed to identify hepatitis C virus (HCV) infection prevalence, and the viral genotypes among patients with hemophilia and other inherited coagulopathies in Mashhad, Iran. Methods: Medical records of 760 patients with inherited coagulopathies including hemophilia were reviewed in Sarvar Clinic of Mashhad. Plasma samples were subjected to detect antibodies against HCV (anti-HCV) by enzyme-linked immunosorbent assay. HCV RNA and genotypes were determined by a real-time polymerase chain reaction (PCR) method. Results: Totally 128 individuals (16.8%) including patients with hemophilia (n=116) and individuals with other coagulopathies (n=12) were found to be seropositive for anti-HCV. They comprised 122 men and six women with a mean age of 31.6 ± 10.5 years. The PCR results were available for 118 patients, of whom 86 individuals (72.9%) were found to have detectable HCV RNA in their serum. The most frequent genotypes were 1a and 3a (49.1% and 35.8%, respectively). HCV genotypes were not significantly correlated with the patients’ age (p=0.477) as well as with the serum levels of alanine aminotransferase (p=0.655) and aspartate aminotransferase (p=0.332). Conclusion: The patients with blood coagulation disorders had a greater prevalence of HCV infection in comparison with the general population in our region. The most common subgenotypes of HCV were 1a, and 3a, respectively. These results could assist professionals to choose more efficient approaches for the management of their patients. *Corresponding Author: Mohammad Reza Hedayati-Moghaddam; Email: [email protected] Please cite this article as: Badiei Z, Ahmadi-Ghezeldasht S, Sima HR, Habibi M, Khamooshi M, Azimi A, Hedayati-Moghaddam MR. The Prevalence of Hepatitis C Virus (HCV) Infection and Genotypes in Patients with Hemophilia and Other Blood Coagulopathies in Mashhad, Iran. Arch Med Lab Sci. 2021;7:1-7 (e9). https://doi.org/10.22037/amls.v7.3396

Coevolution of HTLV-1-HBZ, Tax, and proviral load with host IRF-1 and CCNA-2 in HAM/TSP patients

Background HTLV-1-associated myelopathy (HAM/TSP) is a progressive neurodegenerative inflammatory condition of HTLV-1 infection. Viral-host interactions are a significant contributor to the symptoms of HTLV-1-associated diseases. Therefore, in this study, the expression of the main regulatory viral factors and proviral load (PVL) and two host transcription molecules were evaluated in HAM/TSP patients. Materials and methods The study population included 17 HAM/TSP patients, 20 asymptomatic carriers (ACs), and 19 healthy controls (HCs). RNA and DNA were extracted from PBMCs for assessment of the gene expressions and PVL assessment using RT-qPCR and TaqMan method. Results HTLV-1-PVL was higher in HAM/TSPs (395.80 ± 99.69) than ACs (92.92 ± 29.41) (P = 0.001). The Tax expression in HAM/TSPs (7.8 ± 5.7) was strongly higher than ACs (0.06 ± 0.04) (P = 0.02), while HTLV-1-HBZ was only increased around three times in HAM/TSPs (3.17), compared to ACs (1.20) and not significant. The host IRF1 expression in HAM/TSPs (0.4 ± 0.31) was higher than ACs (0.09 ± 0.05) (P = 0.02) and also HCs (0.16 ± 0.07) (P = 0.5), but lower in ACs than HCs (p = 0.01). Although, in HAM/TSPs (0.13 ± 0.09) and ACs (0.03 ± 0.02) CCNA-2 expression was statistically fewer than HCs (0.18 ± 0.06) (P = 0.03, P = 0.001, respectively), in HAM/TSP was higher than ACs (P = 0.1), but did not meet a 95% confidence interval. Conclusion The study showed that HTLV-1-PVL and Tax, along with host IRF-1, could be considered biomarkers in HAM/TSP development. Furthermore, IRF-1, as an essential transcription factor, can be considered a pivotal target in HAM/TSPs treatment